

**TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS**

<b>Name of the Issue:</b>	<b>Jupiter Life Line Hospitals Limited</b>
<b>1. Type of Issue (IPO/FPO)</b>	<b>IPO</b>
<b>2. Issue Size (Rs. Cr)</b>	<b>INR 869.07 Cr</b>
<b>3. Grade of issue along with name of the rating agency</b>	
<b>Name</b>	<b>NA</b>
<b>Grade</b>	<b>NA</b>
<b>4. Subscription Level (Number of times)</b>	65.1026 (excluding the Anchor Investor Portion ) as per the bid book of BSE and NSE After removing multiple and duplicate bids, Cancelled bids or withdrawal bids, RC 10 and Other than RC 10, application bid not registered and rejections cases from the "Bid Book"

Source: Minutes of the Meeting held for the approval and finalization of the Basis of Allotment dated September 13, 2023

**5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges**

<b>Particulars</b>	<b>Percentage</b>
(i) allotment in the issue*	13.50%
(ii) at the end of the 1st Quarter immediately after the listing of the issue**	20.76%
(iii) at the end of 1st FY (March 31, 2024)#	21.75%
(iv) at the end of 2nd FY (March 31, 2025)##	25.66%
(v) at the end of 3rd FY (March 31, 2026)###	25.49%

(\*)Asper the shareholding pattern as on the date of listing.

\*\*As per the shareholding pattern as on September 30, 2023

#As per the shareholding pattern as on March 31, 2024

##As per the shareholding pattern as on March 31, 2025

###As per the shareholding pattern as on March 31, 2026

## 6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated		(Rs in Crores)		
Parameters	1st FY (March 31, 2024)#	2nd FY (March 31, 2025)#	3rd FY (March 31, 2026)#	
Income from operations	1069.50	1261.14	1499.79	
Net Profit for the period	176.61	193.50	194.19	
Paid-up equity share capital	65.57	65.57	65.57	
Reserves excluding revaluation reserves	1103.17	1290.68	1478.52	

#Source : Audited Financial Statements for the financial year 2023-24, 2024-25 & 2025-26 submitted to Stock Exchange

## 7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the National Stock Exchange of India Limited and the BSE Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2026)	Frequently Traded

## 8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2025)	Mr. Amar Manjrekar (DIN : 00463989)	Appointment as Additional Director in the capacity of Non-Executive Independent Director of the Company for a period of five years, with effect from August 09, 2024,
(iii) at the end of 3rd FY (March 31, 2026)	Nil	Nil

Following changes in directors have been updated till May 30, 2026.

- Resignation of Dr. Bhaskar Shah (DIN:- 00007817) from the position of Non - Executive - Non Independent Director, with effect from May 14, 2026 due to preoccupancy and professional commitments.

## 9. Status of implementation of project/ commencement of commercial production

- As disclosed in the offer document: NA
- Actual implementation: NA
- Reasons for delay in implementation, if any: NA

## 10. Status of utilization of issue proceeds

### (i) As disclosed in the offer document:

The Company proposes to utilize Net Proceeds towards funding the following objects:

(in ₹ million)

Sr. No.	Particulars	Amount to be funded from the Net Proceeds	Estimated schedule of deployment of Net Proceeds in Fiscal 2024
1	Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55
2	General Corporate Purpose	11.63	11.63
<b>Total</b>		<b>5,113.18</b>	<b>5,113.18</b>

### (ii) Actual utilization:

(Rs in million)

Item Head	Amount as proposed in the Offer Document	Amount utilized			Total unutilized amount
		As at beginning of the quarter	During the quarter	At the end of the quarter	
Repayment/prepayment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55	Nil	5,101.55	Nil
General Corporate Purposes (GCP)	11.63	11.63	Nil	11.63	Nil
<b>Total</b>	<b>5,113.18</b>	<b>5,113.18</b>	<b>Nil</b>	<b>5,113.18</b>	<b>Nil</b>

Source : Monitoring Agency Report dated May 10, 2024 for the quarter ended March 31, 2024.

### (iii) Reasons for deviation, if any: Nil

## 11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Nil
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	None
(c) Any other reservations expressed by the monitoring agency about the end use of funds	None

Source : Monitoring Agency Report dated May 10, 2024 for the quarter ended March 31, 2024.

## 12. Pricing Data

**Issue Price (Rs.):** 735/-  
**Designated Stock Exchange:** NSE  
**Listing Date:** September 18, 2023

Price parameters	At close of listing day (i.e. September 18, 2023)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day <sup>#</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2024)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	1,075.75	1045.65	1,150.60	1196.5	1653.95	970.00
NIFTY 50	20,133.30	19811.5	21,456.65	22,326.90	22,526.60	17,312.75
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025)			As at the end of 3rd FY after the listing of the issue (March 31, 2026)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	1,596.55	1,770.00	1,067.65	1281.2	1625.00	1198.80
NIFTY 50	23,519.35	26,277.35	21,281.45	22,331.4	26,373.2	21,743.65
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: NSE website

<sup>#</sup> 90<sup>th</sup> Day being 16<sup>th</sup> December, 2023 i.e Saturday, hence the data has been taken from previous working day Friday i.e. 15<sup>th</sup> December, 2023

13. **Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2024) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2025) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2026) <sup>(2)</sup>
EPS	<b>Issuer:</b>	--	--	--	--
	Consolidated (Basic)	13.95	28.65	29.47	29.59
	Consolidated (Diluted)	12.95	28.65	29.47	29.59
	Peer Group :	--	--	--	--
	Apollo Hospitals Enterprise Limited	Basic – 56.97 Diluted – 56.97	Basic – 62.50 Diluted – 62.50	Basic – 100.56 Diluted – 100.56	Basic – 135.04 Diluted – 134.94
	Fortis Healthcare Limited	Basic – 7.80 Diluted – 7.80	Basic – 7.93 Diluted – 7.93	Basic – 10.26 Diluted – 10.26	Basic – 13.80 Diluted – 13.80
	Max Healthcare Institute Limited	Basic – 11.38 Diluted – 11.36	Basic – 10.89 Diluted – 10.84	Basic – 11.07 Diluted – 11.01	Basic – 14.83 Diluted – 14.76
	Narayana Hrudayalaya Limited	Basic – 29.85 Diluted – 29.85	Basic – 38.86 Diluted – 38.86	Basic – 38.90 Diluted – 38.90	Basic – 39.67 Diluted – 39.67
	Global Health Limited	Basic – 12.58 Diluted – 12.57	Basic – 17.80 Diluted – 17.80	Basic – 17.92 Diluted – 17.92	Basic – 20.71 Diluted – 20.66
	Krishna Institute of Medical Sciences Limited	Basic – 42.03 Diluted – 42.03	Basic – 38.75 Diluted – 38.75	Basic – 9.61 Diluted – 9.61	Basic – 6.03 Diluted – 6.03
	Industry Avg:	NA	N.A	N.A	N.A
	P/E	<b>Issuer:</b>	--	--	--

	Consolidated (Basic)	56.76	41.81	54.18	42.24
	Consolidated (Diluted)	56.76	41.81	54.18	42.24
	Peer Group <sup>1</sup>	--	--	--	--
	Apollo Hospitals Enterprise Limited	Basic – 84.64 Diluted – 84.64	Basic – 101.63 Diluted – 101.63	Basic – 65.85 Diluted – 65.85	Basic – 55.01 Diluted – 55.05
	Fortis Healthcare Limited	Basic – 40.26 Diluted – 40.26	Basic – 52.95 Diluted – 52.95	Basic – 68.08 Diluted – 68.08	Basic – 57.61 Diluted – 57.61
	Max Healthcare Institute Limited	Basic – 45.97 Diluted – 45.97	Basic – 75.34 Diluted – 75.68	Basic – 99.07 Diluted – 99.61	Basic – 69.30 Diluted – 69.62
	Narayana Hrudayalaya Limited	Basic – 33.14 Diluted – 33.14	Basic – 32.95 Diluted – 32.95	Basic – 43.48 Diluted – 43.48	Basic – 40.48 Diluted – 40.48
	Global Health Limited	Basic – 53.70 Diluted – 53.70	Basic – 74.37 Diluted – 74.37	Basic – 66.86 Diluted – 66.86	Basic – 46.44 Diluted – 46.55
	Krishna Institute of Medical Sciences Limited	Basic – 45.09 Diluted – 45.09	Basic – 53.11 Diluted – 53.11	Basic – 66.52 Diluted – 66.52	Basic – 103.23 Diluted – 103.23
	Industry Composite:	50.47	N.A	N.A	N.A
RoNW (%)	<b>Issuer:</b>	--	--	--	--
	Consolidated	20.03	15.11	14.27	12.58
	Peer Group:	--	--	--	--
	Apollo Hospitals Enterprise Limited	16.40	13.50	18.34	21.14

	Fortis Healthcare Limited	20.90	8.42	9.08	10.75
	Max Healthcare Institute Limited	62.80	12.58	11.47	13.42
	Narayana Hrudayalaya Limited	35.40	27.38	21.78	17.86
	Global Health Limited	16.20	16.45	14.21	13.99
	Krishna Institute of Medical Sciences Limited	25.70	18.38	19.40	10.77
	Industry Composite:	NA	N.A	N.A	N.A
NAV	<b>Issuer:</b>	--	--	--	--
	Consolidated	64.39	178.24	206.84	235.49
	Peer Group:	--	--	--	--
	Apollo Hospitals Enterprise Limited	378.33	481.75	206.84	658.71
	Fortis Healthcare Limited	46.67	101.50	570.55	131.07
	Max Healthcare Institute Limited	24.14	86.51	96.50	110.43
	Narayana Hrudayalaya Limited	90.50	141.11	177.45	222.02
	Global Health Limited	90.35	108.22	126.10	147.43
	Krishna Institute of Medical Sciences Limited	193.96	228.46	53.45	56.19

	Industry Avg:	NA	N.A	N.A	N.A
--	---------------	----	-----	-----	-----

**Notes:**

- (1) Prospectus dated September 11, 2023.  
(2) Source : Audited Financial Statements for the financial year 2023-24, 2024-25 & 2025-26.

**14. Any other material information**

Particulars	Date											
The Company has informed that one of the object for raising funds from the public was to settle the borrowings obtained from banks by Jupiter Life Line Hospitals Limited ('The Company') and Jupiter Hospital Project Private Limited ('The Material Subsidiary'). The Company and its Material Subsidiary have repaid the proposed borrowed amount from the Banks i.e., ₹ 3464.50 million, while the Material Subsidiary has repaid ₹ 1637.05 million, respectively.	06-Oct- 2023											
The Company has informed about the resignation of M/s. Gala & Associates., Chartered Accountants as Internal Auditor of the Company effective from February 9, 2024.	09-Feb-2024											
The Company has informed about the appointment of M/s. G. M. Kapadia & Co., Chartered Accountants as Internal Auditor of the Company for the financial year 2023-24.	09-Feb-2024											
The Company has informed about the acquisition of land for setting up hospital on lease of 10 years with an annual lease rental of Rs.9.27 Crores at Bibviewadi, Pune, with an area of ~11,500 Sq. Meter	22-Feb-2024											
The Company has informed about the assigning of ratings on bank facilities as follows :	27-March-2024											
<table border="1"> <thead> <tr> <th>Name of Agency</th> <th>Credit Facilities</th> <th>Assigned Rating</th> <th>Remark</th> </tr> </thead> <tbody> <tr> <td rowspan="2">ICRA Limited</td> <td>Long term Scale</td> <td>[ICRA] A+ (Stable)</td> <td>Upgraded from [ICRA] A (Stable)</td> </tr> <tr> <td>Short term Scale</td> <td>[ICRA] A1</td> <td>Upgraded from [ICRA] A2+</td> </tr> </tbody> </table>	Name of Agency	Credit Facilities	Assigned Rating	Remark	ICRA Limited	Long term Scale	[ICRA] A+ (Stable)	Upgraded from [ICRA] A (Stable)	Short term Scale	[ICRA] A1	Upgraded from [ICRA] A2+	
Name of Agency	Credit Facilities	Assigned Rating	Remark									
ICRA Limited	Long term Scale	[ICRA] A+ (Stable)	Upgraded from [ICRA] A (Stable)									
	Short term Scale	[ICRA] A1	Upgraded from [ICRA] A2+									
The Company has informed about the approval of board for addition of 75 beds capacity in the existing Indore Hospital and 22 beds capacity in the existing Pune Hospital	10-May-2024.											
The Company has informed about the appointment of M/s. Yogesh Sharma & Co, as the Secretarial Auditor of the Company for financial year 2024-25	10-May-2024.											
The Company has informed about the appointment of M/s. V. J. Talati & Co as the Cost Auditor of the Company for financial year 2024-25	10-May-2024											
The Company has informed about the resignation of M/s. B. Mantri & Co., Chartered Accountants (Firm Registration No.: 013559C), the statutory auditor of its Material Subsidiary i.e. Jupiter Hospital Projects Private Limited which will take effect on submission of Limited Review Report for the quarter ended on June 30, 2024.	01-August-2024											
The Company has informed about the appointment of M/s. Varma & Varma, Chartered Accountants, as the Internal Auditor of the Company for financial year 2024- 25.	09-August-2024											
The Company has informed about the appointment of M/s. Shah Valera & Associates LLP as the Statutory Auditor of its material subsidiary namely Jupiter Hospital Projects Private Limited for the term of 5 years from the conclusion of this 13th Annual General Meeting until the conclusion of the 18th Annual General Meeting to be held in the year 2029.	06-September-2024											
The Company has informed about the change in the designation of Mr. Sumit Goda (Senior Management Personnel), from Corporate Head – Supply Chain & Central Purchase Unit to Chief Commercial Officer of the Company with effective from September 14, 2024.	14-September-2024											
The Company has informed about the capacity addition in its existing Indore Hospital and the Pune Hospital, Baner.	01-January-2025											

The Company further informed that an additional 78 beds at Indore Hospital have become operational as of January 1, 2025. As a result, the current capacity of the Company and its subsidiary now stands at 1,061 beds.		
The Company has informed about the purchase of land by the Company for setting up hospital at Ghodbundar Mira Road, District Thane, with an area of 8,433 Sq. Meter.		20-January-2025
The Company has informed about the assigning of credit ratings by ICRA Limited for the bank facilities availed by the Company as mentioned below :		03-February-2025
Credit Facilities	Assigned Rating	Remark
Long term Scale	[ICRA] A+ (Stable), Reaffirmed	Reaffirmation of the same rating as assigned last time
Short term Scale	[ICRA] A1, Reaffirmed	
The Company has inform about the		
The Company has informed about the receipt of necessary regulatory approval for to construct a new hospital at Bibvewadi, Pune & further with these approvals, the company will commence construction from March, 2025.		07-February-2025
The Company has inform about the conversion of a partnership firm (in which the Company holds a 95% of partnership stake) namely Jupiter Pharmacy into Private Limited Company (without any change in the ownership structure).		04-March-2025
The Company further informed that pursuant to the above conversion of Jupiter Pharmacy to Jupiter Hospital Pharmacy Private Limited ("JHPPL"), JHPPL will now be a subsidiary of Jupiter Life Line Hospitals Limited ("Holding Company/Company").		
The Company has informed about the entering of loan agreement by the Company & Jupiter Hospitals Projects Private Limited ("JHPPL"), material subsidiary of Company with HDFC Bank Limited availing loan facility exclusively towards repayment of Intercorporate Loan availed by the Company		24-March-2025
The Company has informed about the following changes in its management as follows :		09-May-2025
<ol style="list-style-type: none"> <li>1) Appointment of Dr. Ankit Thakker as a Joint Managing Director and Chief Executive Officer of the Company, for a period of five years with effect from July 11, 2025 till July 10, 2030, subject to approval of the members of the Company at the ensuing annual general meeting.</li> <li>2) Appointment of Mr. Sivasis Sen as the Chief Financial Officer of the Company with effect from May 12, 2025.</li> <li>3) Appointment of M/s. KKC &amp; Associates LLP, Chartered Accountants as the Statutory Auditor of the Company for the term of five years from the conclusion of the 23rd Annual General Meeting ('AGM') till the conclusion of the 28th AGM, subject to the approval by the members of the Company at the ensuing AGM.</li> <li>4) Appointment of M/s. Yogesh Sharma &amp; Co, Company Secretaries in Practice, as Secretarial Auditors of the Company, for a period of five consecutive years, commencing from FY 2025-2026 to FY 2029-2030, subject to approval of the members of the Company at the ensuing annual general meeting.</li> <li>5) Appointment of M/s. V. J. Talati &amp; Co., Cost Accountant as Cost Auditor of the Company for conducting Cost Audit for FY 2025-2026.</li> <li>6) the change in designation of Dr. Shilpa Tatake from Chief Operating Officer to Chief Executive Officer, Thane, Senior Management Personnel (SMP) of the Company with effect from May 09, 2025.</li> <li>7) the change in designation of Mr. Pradip Acharya from Head – Corporate Relations to Group Head – Industrial Health of the Company with effect from May 09, 2025. In view of the same, Mr. Pradip Acharya ceases to act as a Senior Management Personnel of the Company.</li> </ol>		
The Company has informed about its board approval for the following subject matter :		
<ol style="list-style-type: none"> <li>1) The Scheme of Amalgamation of wholly-owned subsidiary of the Company, viz., Medulla Healthcare Private Limited [hereinafter collectively referred to as the "Transferor Company" with Jupiter Life Line Hospitals Limited (hereinafter referred to as the "Transferee Company" or the "Company" or "JLHL") under</li> </ol>		09-May-2025.

<p>Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with relevant rules &amp; regulations framed thereunder.</p> <p>2) Addition to other object clause of the Memorandum of Association, subject to approval of the members of the Company at the ensuing annual general meeting.</p>																
<p>The Company has informed about the order passed by the NCLT, which allowed the First Motion Application filed in connection with the Scheme of Amalgamation between Medulla Healthcare Private Limited (“Transferor Company”), a wholly-owned subsidiary of Jupiter Life Line Hospitals Limited (“Transferee Company” or “the Company”), together referred to as the “Applicant Companies.</p> <p>The Company further informed that NCLT, vide its Order, has inter alia dispensed with the requirement to convene meetings of the Equity Shareholders, Secured Creditors, and Unsecured Creditors of both the applicant Companies.</p>	11-September - 2025															
<p>The Company has informed that the Hon’ble National Company Law Tribunal, Mumbai Bench (“NCLT”), vide its order (“Order”), has modified its earlier directions regarding service of notice to creditors for the proposed Scheme of Amalgamation between Medulla Healthcare Private Limited (“Transferor Company”), a wholly-owned subsidiary of Jupiter Life Line Hospitals Limited (“Transferee Company” or “the Company”) together referred to as the “Applicant Companies.”</p> <p>The Company further informed that The NCLT has directed that the notice of the proposed Scheme be served only upon those unsecured creditors whose outstanding value exceeds Rs 50,000 (“Rupees fifty thousand”)</p>	18-November- 2025															
<p>The Company has informed about the successful completion of its new Hospital in Dombivli, with all major requisite licenses.</p> <p>The Company further informed that the Dombivli Hospital will be formally commencing 200 operational beds post inauguration on February 15, 2026.</p>	30-January- 2026															
<p>The Company has informed that ICRA Limited (“ICRA”) has assigned the ratings on bank facilities availed by Jupiter Hospital Projects Private Limited, a material subsidiary of Jupiter Life Line Hospitals Limited (“the Company”) as mentioned below:</p> <table border="1" data-bbox="150 1279 1193 1594"> <thead> <tr> <th>Instrument</th> <th>Rated Amount (Rs. Crore)</th> <th>Rating Action[1]</th> </tr> </thead> <tbody> <tr> <td>Long-term - Fund-based - Term loan</td> <td>250.00</td> <td>[ICRA]AA- (Stable); Assigned</td> </tr> <tr> <td>Short-term - Fund-based – Overdraft</td> <td>5.00</td> <td>[ICRA]A1+; Assigned</td> </tr> <tr> <td>Short-term - Interchangeable limits - Bank guarantee</td> <td>(4.00)</td> <td>[ICRA]A1+; Assigned</td> </tr> <tr> <td>Total</td> <td>255.00</td> <td></td> </tr> </tbody> </table>	Instrument	Rated Amount (Rs. Crore)	Rating Action[1]	Long-term - Fund-based - Term loan	250.00	[ICRA]AA- (Stable); Assigned	Short-term - Fund-based – Overdraft	5.00	[ICRA]A1+; Assigned	Short-term - Interchangeable limits - Bank guarantee	(4.00)	[ICRA]A1+; Assigned	Total	255.00		10-March-2026
Instrument	Rated Amount (Rs. Crore)	Rating Action[1]														
Long-term - Fund-based - Term loan	250.00	[ICRA]AA- (Stable); Assigned														
Short-term - Fund-based – Overdraft	5.00	[ICRA]A1+; Assigned														
Short-term - Interchangeable limits - Bank guarantee	(4.00)	[ICRA]A1+; Assigned														
Total	255.00															
<p>The Company has informed about the receipt of a letter from Mumbai Metropolitan Region Development Authority (MMRDA) for allotment of land on lease basis for 80 years at Bandra Kurla Complex, Mumbai.</p> <p>The Company further informed that the aforementioned land (approx. 10,026 sqm) is allotted for ₹354 crore and will be used to set up a 400-bed hospital, subject to necessary approvals.</p>																
<p>The Company has informed about its board approval for Sub-division/ split of 1 (One) existing equity share of the Company having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up, into 5 (Five) equity shares of the Company having face value of Rs. 2/- (Rupee Two only) each, fully paid-up.</p> <p>The Company further informed that in furtherance above, Board has also accorded its approval for the alteration of the Capital Clause of the Memorandum of Association of the Company and Deletion/alteration/modification of Definition &amp; Clauses in Articles of Association of the Company so as to give effect to the aforesaid sub-division of equity shares,</p>	15-05-2026															

<p>The Company has informed about the following changes in its Management :</p> <ol style="list-style-type: none"> <li>1) Considered and approved appointment with change in designation of Dr. Ajay Thakker (DIN: 00120887) from Chairman &amp; Managing director to a Chairman &amp; Whole Time Director for a period of five years with effect from July 17, 2026.</li> <li>2) Appointment of Mr. Aditya Gupta, Senior Vice President – Corporate Affairs as senior managerial personnel of the company w.e.f May 15, 2026.</li> <li>3) Appointment of Dr. Tushar Patil, Head Operations, Dombivli as senior managerial personnel of the company w.e.f May 15, 2026.</li> <li>4) appointment of M/s V.J. Talati &amp; Co. as the Cost Auditor of the Company for the FY 2026-27 w.e.f May 15, 2026.</li> </ol>	<p>15-05-2026</p>
<p>The Company has informed about the resignation of Mr. Sivasis Sen from the position of Chief Financial Officer of the Company with effect from May 31, 2026 due to personal commitments.</p>	<p>18-05-2026</p>

Source- Stock Exchange Filings

All the above information has been updated till May 30, 2026, unless indicated otherwise